reactions (16) .
Chemokines are involved III different inflammatory states, including the regulation of leukocyte trafficking, the immunomodu1ation of leukocyte activation, fibrosis, angiogenesis, and hematopoiesis (17) . Chemokines comprise four supergene families, classified into groups on the basis of the number and arrangement of conserved amino acid sequences at the N terminus (18) . Two of these families: CC and CXC chemokine groups, contain over 50 identified ligands and at least 14 individual receptors. Two additional chemokine families: C and CXXXC (CX 3C) chemokines, are small and contain, respectively, lymphotactin and fractalkine as their members (19) (20) (21) . The chromosomal position in the human genome for CXC is 4q12-21 and 10q, for CC is 7q 11, 17q11-32, 16q13 and 9, for Cis lq23 and for CX 3C is 16ql3.
CXC chemokines, such as interleukin-8 (IL-8), target predominantly neutrophils, whereas CC chemokines such as RANTES and eotaxin target a variety of cell types including macrophages, eosinophils, basophils and mast cells (22) (23) . The CC chemokines are divided into several sub-groups including macrophage chemoattractant protein MCP-1, -2, -3 and -4, and eotaxin. However, it has been shown recently that, after the appropriate stimuli, the CC chemokine receptors CCR1 and CCR3 can be expressed on neutrophils, indicating a wider role for CC chemokines than mononuclear cell activation and recruitment (24) , see Table I .
Chemokines are intimately involved in the initiation and maintenance of allergic diseases and they could be attractive therapeutic targets for the treatment of allergic diseases, including asthma (25) . They are inflammatory proteins acting via G-protein-coupled chemokine receptors that trigger different signaling pathways, and in the cell membrane, chemokines function as leukocyte adhesion molecules (26) . The biological effects of chemokines are mediated by the interaction of these soluble proteins with specific receptors, which belong to the superfamily of seven-transmembrane G-protein-coupled receptors (27) .
The induction of chemokine by several stimulants can be suppressed by glucocorticoids which decrease inflammation. NF-kB, a nuclear factor activated following stimulation of cells with various cytokines, has been shown to be relevant for the transcriptional activation of selected chemokines (28) (29) . There is clear evidence that in allergic inflammation there is overproduction of growth factors and proinflammatory cytokine secretion with inflammatory cell activation with 'overactive' mast cells, T cells, eosinophils, and neutrophils (30) . Human mast cells express numerous chemokine receptors, however, controversial results have been published regarding this distinct chemokine receptor profile on leukocytes and particularly in allergic diseases. It has been reported that three chemokine receptors CCR3, CCR4, and CCR8 are preferentially expressed by mast cells and therefore represent therapeutic targets for allergy (31) (32) (33) . In addition, a subset of chemokines including CCL 111 eotaxin-I, (CCL24/eotaxin-2, (CCL261 eotaxin-3, CCL7/MCP-3, CCLl3/MCP-4, and CCL221 MDC are highly expressed in allergic inflammation and are regulated by T helper type 2 cytokines (34) (35) (36) (37) . Receptors for these chemokines, including CCR3 (CC chemokine receptor 3), CCR4 (CC chemokine receptor 4) and CCR8 (CC chemokine receptor 8) are expressed on key leukocytes associated with allergic inflammation Table I (38) (39) (40) (41) (42) (43) . Inhibitory antibodies and chemokine antagonists support the concept that interfering with this subset of chemokines and their receptors represents a new approach to allergy and inflammation immunotherapy (44) .
The inhibition ofchemokines with corresponding antibodies or other inhibitors may provide benefits in different clinical scenarios including cancer, inflammation, CNS disorders, parasitic disease, heart diseases and immunodysfunctions including autoimmune diseases (45) (46) (47) (48) . Mast cells express on their surface membrane a glycoprotein that binds monomeric immunoglobulin E with high affinity. This Fc£RI receptor is found exclusively on these cells and plays an important and relevant role in allergy by mediating cellular secretion after exposure to allergen (49) (50) (51) (52) (53) (54) .
Mast Cells
Mast cells were discovered over a century ago and they have always excited the curiosity of morphologists, biochemists, physiologists, pharmacologists, immunologists and even general practitioners. These cells express mediators such European Journal oflnllammation as histamine, leukotrienes and prostanoids, as well as proteases, and many cytokines and chemokines pivotal to the genesis of an inflammatory response (55) (56) (57) (58) (59) . The mast cell granule-derived serine proteases provide perhaps the best support for the concept that granule proteins signal both innate host defenses and adaptive immunity.
Mast cells are derived from a unique bone marrow precursor, and they mature in the tissues. Mature mast cells can be isolated from human mononuclear cells of umbilical cord blood cultured in appropriate conditions. After 2-3 months they are transformed in completely granulated, well-preserved human mast cells. Therefore, mast cells develop from progenitor cells, primed with stem cell factor (SCF), which mediates its actions by interacting with the SCF receptor or c-kit on the cell surface. The addition of IL-5 to human umbilical cord blood-derived cultured mast cells was recently shown to augment IgE-induced production of distinct cytokines, such as tumor necrosis factor-alpha (TNF-alpha), macrophage inflammatory protein-I (MIP-I) and GM-CSF (60) .
Mast cells are important in reactions of allergic disease and are also involved in a variety of neuroinflammatory diseases and they can be immunologically activated by IgE through their Fe receptors, as well as by neuropeptides and cytokines/chemokines to secrete mediators (31, 35) . They are commonly known for their role in allergic and anaphylactic reactions, during which they secrete numerous vasoactive, chemoattractant, and inflammatory molecules as well as growth factors (61) (62) (63) (64) (65) .
Mast cells continue their maturation and differentiation in peripheral tissue, developing into two well described subsets of cells, MCT and MCTC cells, varying in content of tryptase and chymase as well as in immunobiology. The majority of these cells contain both tryptase and chymase, condensed chromatin, large nucleoli, elongated mitochondria, free ribosomes, variable numbers of granules containing also cathepsin (a neutral serine proteinase), and spiral and scroll granules that can be seen at high magnifications by an electro microscopy or revealed by light microscopic immunohistochemistry (66) .
Mast cells play an essential role in diverse physiological and pathological processes, such as atherosclerosis, malignancy, asthma, pulmonary fibrosis and arthritis, and directly interact with bacteria and appear to play a vital role in host defense against pathogens (11) . They are located in mucosal and peribroncho-vascular areas, are known to be important in allergic reactions and may play an active role in such diverse diseases (17, 22) . These cells have the capacity to release a variety of mediators that can cause allergic reactions, activate and/or attract other inflammatory cells in the tissue, and possibly increase allergic diseases (30) . Another way of mast cell activation is due to the cytokines/chemokines and other compounds, such as neurotransmitters, which lead to a plethora of biochemical and morphological changes that provoke cell activation and chemokine release without degranulation (18) (19) (20) . The migration of mast cells is also due to many other humoral factors, including those involved in inflammatory process, such as LTB4, C3a, C5a, histamine, PAF, and CRP which have a non-specific chemoattraction on immunity cells. In addition to IgE and antigen, anaphylatoxins (C3a, C5a), cytokines (IL-I, SCF), and neuropeptides (SP, NT, CGRP, NGF) can trigger mast-cell activation leading to secretion of numerous mediators but through different pathways (30) (31) . Mast cells secrete growth factors, such as PDGF, SCF and NGF and also secrete histamine that could induce immunosuppression through H2 receptors.
MCP-I, a CC chemokine that binds CCR2, has been shown to induce allergic reaction by the activation of mast cells. Activation of mast cells with MCP-l causes the release of histamine, leukotrienes, platelet-activating factor and various proteases that either directly mediate inflammation or further enhance the recruitment of leukocytes (Table I) (34) (35) . Mast cells might, therefore, act as a new target for the adjuvant treatment of inflammation and allergic reactions. Clinical evidence of elevated chemokine and chemokine receptor levels in allergic diseases suggest that chemokines and their receptors seem to be effective targets for the development of therapeutic interventions to be used in addition to current therapy for the treatment of allergic and inflammatory diseases (Table II) . The expression of chemokines/cytokines by immune cells is also crucial to autoimmunity by trafficking inflammatory T cells into the central-nervous system.
